• Explore /
  • Poster
  • / TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Abstract Poster

Authors

null

Alexandra Leary

Gustave-Roussy Cancer Campus, Villejuif, and GINECO, Paris, France

Alexandra Leary , Laurence Gladieff , Renaud Sabatier , Xavier Paoletti , Frederik Marmé , Toon Van Gorp , Jerome Alexandre , Thomas Grellety , Antoine Angelergues , Victor Simmet , Julien Grenier , Paule Augereau , Michel Fabbro , Pierre Combe , Anne-Claire Hardy-Bessard , Emilie Kaczmarek

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04713514

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5618)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5618

Abstract #

TPS5618

Poster Bd #

310a

Abstract Disclosures

Similar Posters

First Author: Alexandra Leary

First Author: Enriqueta Felip

First Author: Fabian Trillsch

First Author: Rebecca L. Porter